ArticleFrontiers in endocrinology2025
Parathyroid carcinoma as an overlooked etiology of osteoporosis in postmenopausal women: a case report.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parathyroid carcinoma (PC), an extremely rare endocrine malignancy, disrupts calciumphosphorus homeostasis and lead to musculoskeletal system disorders including osteoporosis, bone pain and pathological fractures. For postmenopausal women, osteoporosis is a common disease. Therefore, secondary osteoporosis is often overlooked in this demographic. We report a 54-year-old woman presenting to Orthopedics Department due to arthralgia diagnosed with severe postmenopausal osteoporosis (PMO). After pharmacotherapy, the patient's symptoms did not show significant improvement. Subsequent endocrine evaluation revealed hyperparathyroidism as the underlying cause. Following parathyroidectomy, histopathological evaluation confirmed the diagnosis of PC and her osteoporosis symptoms improved. This case highlights the critical need for postmenopausal women with osteoporosis to determine whether their condition is primary or secondary in nature. Moreover, the therapeutic principles for managing primary and secondary osteoporosis differ substantially. Early etiological identification is essential to optimize management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.